Ripretinib Safer Than Sunitinib for GIST, Fails to Improve PFS

The findings suggest that ripretinib (Qinlock) provides a similar PFS benefit but may come with notably better tolerability compared with sunitinib.

Related Keywords

Boston ,Massachusetts ,United States ,Oregon ,Dana Farber Cancer Institute ,American ,Michaelc Heinrich , ,American Society Of Clinical Oncology Plenary Series ,Theseus Pharmaceuticals ,Oregon Health Science University ,Harvard Medical School ,Deciphera Pharmaceuticals ,Sarcoma Center At Dana Farber Cancer Institute ,Novartis ,Oregon Health ,Science University ,American Society ,Clinical Oncology Plenary ,Sarcoma Center ,Harvard Medical ,Blueprint Medicines ,Gist ,Gastrointestinal Stromal Tumor ,Umor Gastrointestinal Stromal ,Biologic Therapy ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Ituximab ,Rastuzumab ,Neoplasm ,Toxicology ,Tumor ,Tolerance ,Sarcoma ,Malignant Soft Tissue Tumor ,Alopecia ,Diarrhea ,Fatigue ,Us Fo ,